Peripheral nervous system manifestations of sjögren syndrome: Clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies

Neurologist

Volumn 16, Issue 5, 2010, Pages 287-297

  Birnbaum, Julius ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

fibromyalgia; ganglionopathies; myalgia; neurologic complications; neuronopathies; peripheral nervous system; sensory neuropathies; Sjogren's; skin biopsy; small fiber neuropathies; vasculitic neuropathies

Indexed keywords

ADALIMUMAB; CARBAMAZEPINE; DESIPRAMINE; DULOXETINE; ERGOCALCIFEROL; GABAPENTIN; IMMUNOGLOBULIN; LA ANTIBODY; NICOTINIC RECEPTOR; NORTRIPTYLINE; PREGABALIN; RITUXIMAB; RO ANTIBODY; VENLAFAXINE;

AUTONOMIC NEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE TITRATION; DRY EYE; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOKED RESPONSE; FATIGUE; FIBROMYALGIA; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOBLOTTING; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; LIP BIOPSY; MONONEUROPATHY; MUSCLE BIOPSY; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; MYOSITIS; NERVE BIOPSY; NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROPATHY; PERIPHERAL NERVOUS SYSTEM; PHYSICAL EXAMINATION; POLYNEUROPATHY; PRIORITY JOURNAL; PROPRIOCEPTION; RADIOASSAY; REVIEW; RHEUMATOLOGY; SALIVATION; SARCOIDOSIS; SENSORY GANGLIONOPATHY; SENSORY NEUROPATHY; SERODIAGNOSIS; SIALOGRAPHY; SJOEGREN SYNDROME; SKIN BIOPSY; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VITAMIN D DEFICIENCY; WESTERN BLOTTING; XEROSTOMIA;

ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; RIBONUCLEOPROTEINS; SENSATION DISORDERS; SJOGREN'S SYNDROME;

EID: 77957769725     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181ebe59f     Document Type: Review

References (88)

1. Fox RI. Sjögren's syndrome. Lancet. 2005;366:321-331.
2. Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women ofprimary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol. 2004;33:39-43.
3. Delaleu N, Jonsson MV, Appel S, et al. New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am. 2008;34:833-845, vii.
4. Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, et al. Pathophysiology ofSjögren's syndrome. Arch Med Res. 2006;37:921-932.
5. Segal B, Carpenter A, Walk D. Involvement of nervous system pathways in primary Sjögren's syndrome. Rheum Dis Clin North Am. 2008;34:885-906, viii.
6. Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33:95-106.
7. Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol Suppl. 2000;61:6-10.
8. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
9. Daniels TE, Fox PC Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am. 1992;18:571-589.
10. Bloch KJ, Buchanan WW, Wohl MJ, et al. Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. 1965. Medicine (Baltimore). 1992;71:386-401; discussion401-403.
11. Sutcliffe N, Inanc M, Speight P, et al. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum. 1998;28:80-87.
12. Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality ofprimary Sjögren's syndrome. Semin Arthritis Rheum. 2000; 29:296-304.
13. Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38:245-253.
14. Harboe E, Tjensvoll AB, Maroni S, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis. 2009;68:1541-1546.
15. Andonopoulos AP, Lagos G, Drosos AA, et al. The spectrum ofneurological involvement in Sjögren's syndrome. Br JRheumatol. 1990;29:21-23.
16. Govoni M, Bajocchi G, Rizzo N, et al. Neurological involvement in primary Sjögren's syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol. 1999;18:299-303.
17. Moll JW, Markusse HM, Pijnenburg JJ, et al. Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome. Neurology. 1993;43:2574-2581.
18. Hietaharju A, Yli-Kerttula U, Hakkinen V, et al. Nervous system manifestations in Sjögren's syndrome. Acta Neurol Scand. 1990;81:144-152.
19. Kaltreider HB, Talal N. The neuropathy ofSjögren's syndrome. Trigeminal nerve involvement. Ann Intern Med. 1969;70:751-762.
20. Drosos AA, Andonopoulos AP, Lagos G, et al. Neuropsychiatric abnormal-ities in primary Sjögren's syndrome. Clin Exp Rheumatol. 1989;7:207-209.
21. Molina R, Provost TT, Arnett FC, et al. Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features. Am JMed. 1986;80:23-31.
22. Pease CT, Shattles W, Charles PJ, et al. Clinical, serological, and HLA phenotype subsets in Sjögren's syndrome. Clin Exp Rheumatol. 1989;7:185-190.
23. Martinez-Lavin M, Vaughan JH, Tan EM. Autoantibodies and the spectrum ofSjögren's syndrome. Ann Intern Med. 1979;91:185-190.
24. Mauch E, Volk C, Kratzsch G, et al. Neurological and neuropsychiatric dysfunction in primary Sjögren's syndrome. Acta Neurol Scand. 1994;89: 31-35.
25. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210-219.
26. Molina JA, Benito-Leon J, Bermejo F, et al. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry. 1996;60:699.
27. Birnbaum J. Peripheral neuropathy is an uncommon cause of neuropathic symptoms in Sjögren's patients. Arthritis Rheum. 2009;60(suppl 10):506.
28. Segal B, Bowman SJ, Fox PC, et al. Prevalence of sensory symptoms in primary Sjögren's syndrome (PSS) andrelationship ofneuropathic symptoms to depression and fibromyalgia. Arthritis Rheum. 2007;56(suppl):S448.
29. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis ofsensoryneuronopathies (ganglionopathies). Muscle Nerve. 2004;30: 255-268.
30. O'Leary CP, Willison HJ. Autoimmune ataxic neuropathies (sensory gangli-onopathies). Curr Opin Neurol. 1997;10:366-370.
31. Sharp FR, Rando TA, Greenberg SA, et al. Pseudochoreoathetosis. Movements associated with loss ofproprioception. Arch Neurol. 1994;51:1103-1109.
32. Mori K, Iijima M, Koike H, et al. The wide spectrum ofclinical manifesta-tions in Sjögren's syndrome-associated neuropathy. Brain. 2005;128:2518-2534.
33. Grant IA, Hunder GG, Homburger HA, et al. Peripheral neuropathy associ-ated with sicca complex. Neurology. 1997;48:855-862.
34. Kuntzer T. Ganglionopathies: evolving concept and ideas on management. Rev Neurol (Paris). 2006;162:1268-1272.
35. Mori K, Koike H, Misu K, et al. Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neu-ronopathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychi-atry. 2001;71:488-492.
36. Pascual J, Cid C, Berciano J. High-dose i. v. immunoglobulin for peripheral neuropathy associated with Sjögren's syndrome. Neurology. 1998;51:650-651.
37. Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain. 2005;128:2480-2482.
38. Takahashi Y, Takata T, Hoshino M, et al. Benefit ofIVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin Neurology. 2003;60:503-505.
39. Mellgren SI, Goransson LG, Omdal R. Primary Sjögren's syndrome associ-ated neuropathy. Can J Neurol Sci. 2007;34:280-287.
40. Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol. 1990;27:304-315.
41. Malinow K, Yannakakis GD, Glusman SM, et al. Subacute sensory neu-ronopathy secondary to dorsal root ganglionitis in primary Sjögren's syn-drome. Ann Neurol. 1986;20:535-537.
42. Eystathioy T, Chan EK, Tenenbaum SA, et al. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population ofhuman mRNAs withinnovel cytoplasmic speckles. Mol Biol Cell. 2002;13:1338-1351.
43. Bhanji RA, Eystathioy T, Chan EK, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol. 2007;125:247-256.
44. Lopate G, Pestronk A, Al-Lozi M, et al. Peripheral neuropathy in an outpatient cohort ofpatients with Sjögren's syndrome. Muscle Nerve. 2006; 33:672-676.
45. Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjogren syndrome: a population-based study. Arch Neurol. 2006;63: 1612-1615.
46. Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002;26:173-188.
47. Kennedy WR, Wendelschafer-Crabb G, Walk D. Use of skin biopsy and skinblister inneurologic practice. JClin Neuromuscul Dis. 2000;1:196-204.
48. Holland NR, Crawford TO, Hauer P, et al. Smallfiber sensory neuropathies: clinical course and neuropathology ofidiopathic cases. Ann Neurol. 1998;44: 47-59.
49. Novak V, Freimer ML, Kissel JT, et al. Autonomic impairment in painful neuropathy. Neurology. 2001;56:861-868.
50. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology. 1999;53:1641-1647.
51. Chai J, Herrmann DN, Stanton M, et al. Painful small-fiber neuropathy in Sjogren syndrome. Neurology. 2005;65:925-927.
52. Tavee J, Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin JMed. 2009;76:297-305.
53. Freynhagen R, Bennett MI. Diagnosis and management ofneuropathic pain BMJ. 2009;339:b3002.
54. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness oftherapy. Pharmacoeconomics. 2009;27:95-112.
55. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21.
56. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment ofneuropathic pain. Eur JNeurol. 2006;13:1153-1169.
57. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-basedrecommendations. Pain. 2007;132:237-251.
58. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234-241. (Pubitemid 38314873)
59. Arvold DS, Odean MJ, Dornfeld MP, et al. Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. Endocr Pract. 2009;15:203-212.
60. Wakasugi D, Kato T, Gono T, et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome. Mod Rheumatol. 2009;19:437-440.
61. Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci. 2009;15:279:57-61.
62. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280-291.
63. Gorson KC. Vasculitic neuropathies: an update. Neurologist. 2007;13:12-19.
64. Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005;252:633-641.
65. Stone JH. Vasculitis: a collection of pearls and myths. Rheum Dis Clin North Am. 2007;33:691-739, v.
66. Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66:704-709.
67. Wung PK, Stone JH. Therapeutics of Wegener's granulomatosis. Nat Clin Pract Rheumatol. 2006;2:192-200.
68. Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance ofneuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum. 2007;57:1520-1529.
69. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int. 2009;76:818-824.
70. Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical andpathophysiologic aspects. Medicine (Baltimore). 2009;88:284-293.
71. Lui NL, See SJ, Thumboo J. A rare cause ofreversible unilateral third nerve palsy. J Neurol Sci. 2008;275:188-190.
72. Chu K, Kang DW, Song YW, et al. Trochlear nerve palsy in Sjögren's syndrome. J Neurol Sci. 2000;177:157-159.
73. Rigamonti A, Lauria G, Balgera R, et al. Subacute inflammatory polyradiculopathy associated with Sjögren's syndrome. Muscle Nerve. 2009;39:855-857.
74. Pou Serradell A, Vinas Gaya J. 3 cases of rare peripheral neuropathies associated with primary Gougerot-Sjogren syndrome. Rev Neurol (Paris). 1993;149:481-484.
75. Sakakibara R, Hirano S, Asahina M, et al. Primary Sjögren's syndrome present-ing with generalized autonomic failure. Eur J Neurol. 2004;11:635-638.
76. Mandl T, Bornmyr SV, Castenfors J, et al. Sympathetic dysfunction in patients with primary Sjögren's syndrome. J Rheumatol. 2001;28:296-301.
77. Mandl T, Granberg V, Apelqvist J, et al. Autonomic nervous symptoms in primary Sjögren's syndrome. Rheumatology (Oxford). 2008;47:914-919.
78. Mandl T, Wollmer P, Manthorpe R, et al. Autonomic and orthostatic dys-function in primary Sjögren's syndrome. J Rheumatol. 2007;34:1869-1874.
79. Barendregt PJ, Tulen JH, van den Meiracker AH, et al. Spectral analysis of heart rate and blood pressure variability in primary Sjögren's syndrome. Ann Rheum Dis. 2002;61:232-236.
80. Hocevar A, Tomsic M, Praprotnik S, et al. Parasympathetic nervous system dysfunction in primary Sjögren's syndrome. Ann Rheum Dis. 2003;62:702-704.
81. Bacman S, Sterin-Borda L, Camusso JJ, et al. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunol. 1996;104:454-459.
82. Bacman SR, Berra A, Sterin-Borda L, et al. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res. 1998;17: 1135-1142. (Pubitemid 28562895)
83. Bacman S, Berra A, Sterin-Borda L, et al. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci. 2001;42:321-327.
84. Wang F, Jackson MW, Maughan V, et al. Passive transfer of Sjögren's syndrome igG produces the pathophysiology of overactive bladder. Arthritis Rheum. 2004;50:3637-3645.
85. Nguyen KH, Brayer J, Cha S, et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum. 2001;43:2297-2306.
86. Winston N, Vernino S. Autoimmune autonomic ganglionopathy. Front NeurolNeurosci. 2009;26:85-93.
87. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopa-thies. J Neurol Neurosurg Psychiatry. 2009;80:1060-1068.
88. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med. 2009;122: 793-802.